Myeloma fitness/frailty risk scores
| Frailty score . | Geriatric domains . | Biologic marker . | Cytogenetics included? . | Score range . | Interpretation . |
|---|---|---|---|---|---|
| IMWG6 | ADLs IADLs CCI | None | No | 0-2 | 0 (fit) 1 (intermediate-fit) 2 (frail) |
| R-MCI7 | Age Fried frailty Lung function Renal function Karnofsky performance status | None | Yes | 0-9 | 0-3 (fit) 4-6 (intermediate- fit) 7-9 (frail) |
| Facon frailty scale8 | Age CCI ECOG performance status9 | None | No | 0-1 ≥2 | 0-1 (nonfrail) ≥2 (frail) |
| Myeloma Research Alliance risk profile10 | Age WHO performance status9 | CRP ISS | No | <−0.256 −0.256-−0.0283 >−0.0283 | <−0.256 (low risk) −0.256 to −0.0283 (medium risk) >−0.0283 (high risk) |
| Mayo frailty index11 | Age WHO performance status9 | NT- proBNP | No | 0-3 | 0 (stage 1) 1 (stage 2) 2 (stage 3) 3 (stage 4) |
| Ancona vulnerability score12 | CCI WHO performance status9 | None | No | 0-2 | 0 (low) 1 (intermediate) 2 (high) |
| Frailty score . | Geriatric domains . | Biologic marker . | Cytogenetics included? . | Score range . | Interpretation . |
|---|---|---|---|---|---|
| IMWG6 | ADLs IADLs CCI | None | No | 0-2 | 0 (fit) 1 (intermediate-fit) 2 (frail) |
| R-MCI7 | Age Fried frailty Lung function Renal function Karnofsky performance status | None | Yes | 0-9 | 0-3 (fit) 4-6 (intermediate- fit) 7-9 (frail) |
| Facon frailty scale8 | Age CCI ECOG performance status9 | None | No | 0-1 ≥2 | 0-1 (nonfrail) ≥2 (frail) |
| Myeloma Research Alliance risk profile10 | Age WHO performance status9 | CRP ISS | No | <−0.256 −0.256-−0.0283 >−0.0283 | <−0.256 (low risk) −0.256 to −0.0283 (medium risk) >−0.0283 (high risk) |
| Mayo frailty index11 | Age WHO performance status9 | NT- proBNP | No | 0-3 | 0 (stage 1) 1 (stage 2) 2 (stage 3) 3 (stage 4) |
| Ancona vulnerability score12 | CCI WHO performance status9 | None | No | 0-2 | 0 (low) 1 (intermediate) 2 (high) |
CRP, C-reactive protein; NT-proBNP, N-terminal pro B-type Natriuretic Peptide; WHO, World Health Organization.